Literature DB >> 20448374

Testicular relapse in childhood acute lymphoblastic leukemia: the challenges and lessons.

K P Kulkarni1, R K Marwaha, A Trehan, D Bansal.   

Abstract

BACKGROUND: Relapse of disease is documented in 15-20% of children with acute lymphoblastic leukemia (ALL). Although testicular relapse is rare with modern risk-adapted treatment protocols, earlier, the testes were a frequently encountered site of relapse and were designated as "drug sanctuaries".
PURPOSE: This descriptive study was designed to assess the pattern of testicular relapse and to identify high-risk factors.
MATERIALS AND METHODS: Data obtained from case records of 407 boys with ALL were analyzed. Fine needle aspiration cytology was carried out in children presenting with painless enlargement of testi(e)s. Bone marrow aspiration and cerebrospinal fluid examination were performed concomitantly to confirm or exclude disease at these sites.
RESULTS: Testicular relapse was documented in 30 boys. It was isolated in 17 patients and associated with bone marrow and/or central nervous system relapse in 13. At relapse, nine boys were over the age of 10 years. The majority were very early and early relapsers. Hyperleucocytosis was documented in five of 30 and seven of 137 relapsers and nonrelapsers, respectively (P = 0.04). Twelve of the 30 boys with testicular relapse were treated with testicular irradiation, reinduction and maintenance therapy. The estimated median overall survival was 33 months.
CONCLUSION: Testicular relapse, which depends on the therapy administered, may manifest several months/years after completion of treatment. The high incidence of testicular relapse in our series implicates the need of revaluation of our protocol and incorporation of high/intermediate dose methotrexate therapy upfront.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20448374     DOI: 10.4103/0019-509X.63002

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  7 in total

1.  Successful chimeric Ag receptor modified T cell therapy for isolated testicular relapse after hematopoietic cell transplantation in an acute lymphoblastic leukemia patient.

Authors:  J Yu; Y Hu; C Pu; Z Liang; Q Cui; H Zhang; Y Luo; J Shi; A Jin; L Xiao; Z Wu; H Huang
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

Review 2.  Transepithelial transport across the blood-testis barrier.

Authors:  Siennah R Miller; Nathan J Cherrington
Journal:  Reproduction       Date:  2018-12       Impact factor: 3.906

Review 3.  The Good, the Bad and the Ugly of Testicular Immune Regulation: A Delicate Balance Between Immune Function and Immune Privilege.

Authors:  Gurvinder Kaur; Kandis Wright; Saguna Verma; Allan Haynes; Jannette M Dufour
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Expression of terminal deoxynucleotidyl transferase (TdT) in classical seminoma: a potential diagnostic pitfall.

Authors:  Alexander Brobeil; Florian Wagenlehner; Stefan Gattenlöhner
Journal:  Virchows Arch       Date:  2018-02-18       Impact factor: 4.064

5.  Bilateral macular detachment: Choroid as a sanctuary of acute lymphoblastic leukemia.

Authors:  Agustina Adaniya; Pablo Bazterrechea; José Ignacio Trucco; Bernardo Ariel Schlaen; Gustavo Kusminsky; Mario Joaquin Saravia
Journal:  Am J Ophthalmol Case Rep       Date:  2020-05-13

6.  Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transporters.

Authors:  Siennah R Miller; Joseph L Jilek; Meghan E McGrath; Raymond K Hau; Erin Q Jennings; James J Galligan; Stephen H Wright; Nathan J Cherrington
Journal:  Pharmacol Res Perspect       Date:  2021-08

7.  Recurrence of acute myeloid leukemia in cryptorchid testis: case report.

Authors:  Luccas Santos Patto de Góes; Roberto Iglesias Lopes; Octavio Henrique Arcos Campos; Luiz Carlos Neves de Oliveira; Alexandre Crippa Sant'Anna; Marcos Francisco Dall'Oglio; Miguel Srougi
Journal:  Einstein (Sao Paulo)       Date:  2014 Jan-Mar
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.